Search
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalOlodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesBarnidipine
go.drugbank.com/drugs/DB09227InvestigationalBarnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsPicosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalPicosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfat...
Products: DULCOLAX ® P PERLASRamosetron
go.drugbank.com/drugs/DB09290InvestigationalRamosetron is a serotonin 5-HT3 receptor antagonist commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalNeurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usuall...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMonensin
go.drugbank.com/drugs/DB11430ExperimentalVet approvedMonensin is a polyether isolated from Streptomyces cinnamonensis that presents antibiotic properties. It is widely used in ruminant animal feeds.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAmifampridine
go.drugbank.com/drugs/DB11640ApprovedPatients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnTropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radioth...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates